Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Not yet recruiting · NCT06172036 · Registry updated 2023-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab | Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer | Not yet recruiting | Phase 2 | 2023-12-15 | NCT06172036 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang University | 194 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||